Section Arrow
LGVN.NASDAQ
- Longeveron
(Financial Status)
Quotes are at least 15-min delayed:2026/05/26 08:58 EDT
Pre Market
Last
 0.84
+0.0198 (+2.41%)
Bid
0.84
Ask
0.8499
High 0.9131 
Low 0.82 
Volume 18.53K 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
0.8202 
1-M High
-- 
Volume 
-- 
Bid
0.84
Ask
0.8499
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
25.92M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.14/-0.46
Enterprise Value
26.09M
Balance Sheet
Book Value Per Share
0.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.20M
Operating Revenue Per Share
0.03
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 25.74 +0.13 +0.51%
ZVRAZevra Therapeutics-------- 
Pre Market 10.32 +0.29 +2.89%
ZURAZura Bio Limited-------- 
Pre Market 4.44 +0.08 +1.83%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 4.05 -0.01 -0.25%
ZLABZai Lab Limited-------- 
Pre Market 18.49 -0.12 -0.64%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.